PT  - JOURNAL ARTICLE
AU  - Liu, Hanqing
AU  - Wang, Jiaxi
AU  - Sun, Yaoting
AU  - Zhou, Yan
AU  - Hu, Pingping
AU  - Li, Lu
AU  - Yang, Dan
AU  - Kong, Deguang
AU  - Xu, Zhiliang
AU  - Zhu, Yi
AU  - Guo, Tiannan
AU  - Chen, Chuang
TI  - Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid Cancer
AID  - 10.1101/2024.09.22.24314143
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.22.24314143
4099  - http://medrxiv.org/content/early/2024/09/30/2024.09.22.24314143.short
4100  - http://medrxiv.org/content/early/2024/09/30/2024.09.22.24314143.full
AB  - Background Despite the generally favorable prognosis of papillary thyroid cancers (PTCs) following thyroidectomy and potential radioactive iodine (RAI) therapy, approximately one-third of patients experiencing recurrence and metastasis eventually develop resistance to RAI, leading to a poor outcome. However, the mechanisms underlying RAI-refractoriness remain elusive. The present study aimed to assess the molecular and proteomic characteristics of RAI-refractory PTC (RR-PTC) to gain a deeper understanding of this condition.Methods The medical records at our institution were reviewed for the selection and grouping of RR-PTC patients and RAI-sensitive controls. RR-PTC patients were divided into three subgroups: continuous RAI uptake (ID), loss of uptake at the first I-131 treatment (iDF) and RAI uptake lost gradually (iDG). Proteomic profiling and targeted next-generation sequencing were performed on formalin-fixed paraffin embedded primary lesions. The incidence of gene mutations and fusions was compared across groups. Bioinformatic analysis was subsequently conducted to identify the differentially expressed proteins and enriched pathways. The correlation of protein expression and gene variances was assessed.Results A total of 48 PTC patients with recurrence and/or metastasis were included. The expression profiles of the RR-PTC and control groups were similar. In the subgroup comparison, enriched pathways related to MAPK and TNF signaling were associated with negative I-131 uptake and tumor tolerance with positive I-131 uptake. The BRAFV600E mutation was less common in the ID group, whereas the TERT promoter mutation was more common in the iDF group. NCOA4-RET fusion was more common in the ID group. In addition, four proteins were dysregulated in BRAF-mutated PTCs.Conclusion The present study constructed the first proteomic profile of RR-PTC. The proteins and pathways identified in the analysis may be promising biomarkers and drug targets. Gene alterations and fusions can aid in the early diagnosis of RR-PTC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by grants from the Interdisciplinary Innovative Talents Foundation from Renmin Hospital of Wuhan University (JCRCFZ-2022-015), the Fundamental Research Funds for the Central Universities (2042019kf0229), the Natural Science Foundation of Hubei Province, China (2023AFB701), and the Thyroid Research Project for Young and Middle-aged Doctors from Bethune Charitable Foundation (JKM2022-B12).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethical Committee of Renmin Hospital of Wuhan University gave ethical approval for this study (No. WDRY2021-K032). The requirement for obtaining informed consent from the involved patients was waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe proteomic data have been deposited in the iProX database with the project ID IPX0009103001. Calculation files and additional data are available in the Mendeley database (DOI: 10.17632/yfpfvktrxn). No custom code was used in the current study. https://www.iprox.cn//page/SCV017.html?query=IPX0009103001 https://data.mendeley.com/datasets/yfpfvktrxn/1 ANOVAanalysis of varianceATAAmerican Thyroid AssociationAUCarea under the curve (of ROC)BRAFB-Raf proto-oncogene, serine/threonine kinaseBRSBRAF-RAS scoreCCcorrelation coefficientCOSMICthe Catalogue Of Somatic Mutations In CancerCTcomputed tomographyCYTimmune cytolytic activity scoreDEGdifferentially expressed geneDEPdifferentially expressed proteinDIAdata-independent acquisitionDTCdifferentiated thyroid cancerECPeosinophil cationic proteinESenrichment scoreERKextracellular signal-regulated kinaseETEextrathyroidal extensionFCfold changeFFPEformalin-fixed paraffin-embeddedF-18-FDG2-[18F]fluoro-2-deoxy-D-glucoseGEOthe Gene Expression Omnibus databaseGOgene ontologyGSgene significanceGSEAgene set enrichment analysisGSVAgene set variation analysisHRhazard ratioIDpositive RAI uptake and disease persistenceIdRAI uptake positive and disease remissioniDFnegative RAI uptake at the first time of RAI treatment with disease persistenceiDGRAI uptake lost gradually after previous RAI treatments with disease persistenceIISimmune infiltration scoreIPinositol phosphateIPAingenuine pathway analysisKEGGKyoto Encyclopedia of Genes and GenomesKNNK-nearest neighborLASSOleast absolute shrinkage and selection operatorLCliquid chromatographyLNMlymph node metastatic lesionMAPKmitogen-activated protein kinaseMETMET proto-oncogeneMKImulti-kinase inhibitorMMmodule membershipMSmass spectrometryMRImagnetic resonance imagingNISsodium iodide symporterPCAprincipal component analysisPCTpressure cycling technologyPETpositron emission tomographyRAIradioactive iodineRAIRRAI-refractorinessRFrandom forestRFSrecurrence-free survivalRMArobust multiarray averageROCreceiver operating characteristicRR-PTCradioactive iodine refractory papillary thyroid cancerSPECTsingle photon emission computerized tomographyssGSEAsingle sample GSEASVM-RFEsupport vector machine-recursive feature eliminationTAK1transforming growth factor-βactivated kinase 1TCGAThe Cancer Genome Atlas ProgramTERTtelomerase reverse transcriptaseTERTpTERT promoterTDSthyroid differentiation scoreTIST cell infiltration scoreTNFtumor necrosis factorTNGStargeted next-generation sequencingTOMtopological overlap matrixWBSwhole-body scanningWGCNAweighted correlation network analysis